Using the GEPIA (http://gepia.cancer-pku.cn/detail.php), we found EZH2 expression was significantly decreased in AML patients compared with normal controls (P < .001, Figure 1B), but EZH1 expression showed no difference (P > .05, Figure 1A). This evidence concerns the gene EZH2 and acute myeloid leukemia.